Reach Us +44-1904-929220
A novel Enzyme Inhibition Assay for Screening of Type 1 Diabetes Mellitus | OMICS International | Abstract

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

A novel Enzyme Inhibition Assay for Screening of Type 1 Diabetes Mellitus

Manoochehr Messripour*

Islamic Azad University-Khorasgan branch, Iran

*Corresponding Author:
Manoochehr Messripour
Islamic Azad University-Khorasgan branch Esfahan
E-mail: [email protected]

Received Date: April 30, 2011; Accepted Date: June 20, 2011; Published Date: June 27, 2011

Citation: Messripour M (2011) A novel Enzyme Inhibition Assay for Screening of Type 1 Diabetes Mellitus. J Mol Biomark Diagn 2:107. doi:10.4172/2155- 9929.1000107

Copyright: © 2011 Messripour M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Glutamate decarboxylase (GAD) antibody has been found in patients with recent-onset insulin dependent diabetes mellitus (IDDM). Several analytical methods are described for detection and quantitation of anti-GAD antibodies whereas the inhibition of the enzyme activity by anti-enzyme antibody is given little attention. In this study a quenching fluorimetric method based on changes of fluorescence intensities upon addition antiserum into the enzyme/substrate medium is described. The activity of the purified rat brain GAD was measured by both manometeric and fluorimeteric methods in the presence of serum samples from IDDM patients (n=21) or non diabetic subjects (n=21). Significant differences between the patients and control groups were observed using both methods. However, high degree of fluorescence sensitivity of fluorimetric technique allows for less error, less time and satisfactory useful and economical for screening of IDDM in the large populations.

Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page